

Atopic Dermatitis - Pipeline Review, H2 2019

<https://marketpublishers.com/r/A821E518065EN.html>

Date: November 2019

Pages: 597

Price: US\$ 2,000.00 (Single User License)

ID: A821E518065EN

Abstracts

Atopic Dermatitis - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H2 2019, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 12, 47, 25, 3, 57, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 6 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).

The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA)

and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Atopic Dermatitis (Atopic Eczema) - Overview

Atopic Dermatitis (Atopic Eczema) - Therapeutics Development

Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment

Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development

Atopic Dermatitis (Atopic Eczema) - Drug Profiles

Atopic Dermatitis (Atopic Eczema) - Dormant Projects

Atopic Dermatitis (Atopic Eczema) - Discontinued Products

Atopic Dermatitis (Atopic Eczema) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Table 1: Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 10: Number of Products under Development by Universities/Institutes, H2 2019

Table 11: Products under Development by Companies, H2 2019

Table 12: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 13: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 14: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 15: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 16: Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 17: Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 18: Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 19: Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Table 20: Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Table 21: Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Table 22: Products under Development by Universities/Institutes, H2 2019

Table 23: Number of Products by Stage and Target, H2 2019

Table 24: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 25: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Table 26: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Table 27: Number of Products by Stage and Mechanism of Action, H2 2019

- Table 28: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
- Table 29: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
- Table 30: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
- Table 31: Number of Products by Stage and Route of Administration, H2 2019
- Table 32: Number of Products by Stage and Molecule Type, H2 2019
- Table 33: Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, H2 2019
- Table 34: Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, H2 2019
- Table 35: Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, H2 2019
- Table 36: Atopic Dermatitis (Atopic Eczema) - Pipeline by Aclaris Therapeutics Inc, H2 2019
- Table 37: Atopic Dermatitis (Atopic Eczema) - Pipeline by Afecta Pharmaceuticals Inc, H2 2019
- Table 38: Atopic Dermatitis (Atopic Eczema) - Pipeline by Akaal Pharma Pty Ltd, H2 2019
- Table 39: Atopic Dermatitis (Atopic Eczema) - Pipeline by Allergan Plc, H2 2019
- Table 40: Atopic Dermatitis (Atopic Eczema) - Pipeline by Almirall SA, H2 2019
- Table 41: Atopic Dermatitis (Atopic Eczema) - Pipeline by Amgen Inc, H2 2019
- Table 42: Atopic Dermatitis (Atopic Eczema) - Pipeline by Amorepacific Corp, H2 2019
- Table 43: Atopic Dermatitis (Atopic Eczema) - Pipeline by AOBiome LLC, H2 2019
- Table 44: Atopic Dermatitis (Atopic Eczema) - Pipeline by Apimeds Inc, H2 2019
- Table 45: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arcutis Inc, H2 2019
- Table 46: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arena Pharmaceuticals Inc, H2 2019
- Table 47: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arrien Pharmaceuticals LLC, H2 2019
- Table 48: Atopic Dermatitis (Atopic Eczema) - Pipeline by Asana BioSciences LLC, H2 2019
- Table 49: Atopic Dermatitis (Atopic Eczema) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
- Table 50: Atopic Dermatitis (Atopic Eczema) - Pipeline by Astellas Pharma Inc, H2 2019
- Table 51: Atopic Dermatitis (Atopic Eczema) - Pipeline by AstraZeneca Plc, H2 2019
- Table 52: Atopic Dermatitis (Atopic Eczema) - Pipeline by Atrapos Therapeutics LLC, H2 2019
- Table 53: Atopic Dermatitis (Atopic Eczema) - Pipeline by Azitra Inc, H2 2019
- Table 54: Atopic Dermatitis (Atopic Eczema) - Pipeline by Bausch Health Companies Inc, H2 2019

Table 55: Atopic Dermatitis (Atopic Eczema) - Pipeline by Biomimetix JV LLC, H2 2019

Table 56: Atopic Dermatitis (Atopic Eczema) - Pipeline by Blueberry Therapeutics Ltd, H2 2019

Table 57: Atopic Dermatitis (Atopic Eczema) - Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Table 58: Atopic Dermatitis (Atopic Eczema) - Pipeline by Boston Pharmaceuticals Inc, H2 2019

Table 59: Atopic Dermatitis (Atopic Eczema) - Pipeline by Botanix Pharmaceuticals Ltd, H2 2019

Table 60: Atopic Dermatitis (Atopic Eczema) - Pipeline by Calcico Therapeutics Ltd, H2 2019

List Of Figures

LIST OF FIGURES

Figure 1: Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019

COMPANIES MENTIONED

Abate Med Inc

AbbVie Inc

Abeome Corp

Aclaris Therapeutics Inc

Afecta Pharmaceuticals Inc

Akaal Pharma Pty Ltd

Allergan Plc

Almirall SA

Amgen Inc

Amorepacific Corp

AOBiome LLC

Apimeds Inc

Arcutis Inc

Arena Pharmaceuticals Inc

Arrien Pharmaceuticals LLC

Asana BioSciences LLC

Aslan Pharmaceuticals Ltd

Astellas Pharma Inc

AstraZeneca Plc

Atrapos Therapeutics LLC

Azitra Inc
Bausch Health Companies Inc
Biomimetix JV LLC
Blueberry Therapeutics Ltd
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Botanix Pharmaceuticals Ltd
Calcico Therapeutics Ltd
Celgene Corp
ChironWells GmbH
Chugai Pharmaceutical Co Ltd
Clayton Biotechnologies Inc
Clevexel Pharma SAS
CSA Biotechnologies LLC
Cutanea Life Sciences Inc
Daiichi Sankyo Co Ltd
Dermata Therapeutics LLC
Dermavant Sciences Inc
DermBiont Inc
Devonian Health Group Inc
DongKoo Bio & Pharma Co Ltd
DURECT Corp
EHL Bio Co Ltd
Eli Lilly and Co
Evelo Biosciences Inc
Evotec SE
F. Hoffmann-La Roche Ltd
Fountain Biopharma Inc
Galapagos NV
Galderma SA
General Regeneratives Shanghai Ltd
GI Innovation Co Ltd
GlaxoSmithKline Plc
Helix BioMedix Inc
Hill Dermaceuticals Inc
Hoth Therapeutics Inc
Huons Co Ltd
Ichnos Sciences Inc
Immune Pharmaceuticals Inc

Incyte Corp
Inflamalps SA
Innovation Pharmaceuticals Inc
Innovimmune Biotherapeutics Inc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
JW Pharmaceutical Corp
Kang Stem Biotech Co Ltd
Kine Sciences
Kiniksa Pharmaceuticals Corp
KoBioLabs Inc
Krystal Biotech Inc
Kv1.3 Therapeutics
Kymab Ltd
Kyowa Kirin Co Ltd
Larix Bioscience LLC
Lead Pharma Holding BV
Lemonex Inc
Leo Pharma AS
Lipid Biologics LLC
Lypanosys Pte Ltd
Madam Therapeutics BV
Matrisys Bioscience Inc
MC2 Therapeutics AS
Medicenna Therapeutics Corp
Micareos BV
Nektar Therapeutics
Nepsone ehf
Neuracle Science Co Ltd
NeuroCycle Therapeutics GmbH
Next Science Ltd
NovaCell Technology Inc
Novan Inc
Novartis AG
Oasis Pharmaceuticals LLC
OliX Pharmaceuticals Inc
Ondek Pty Ltd
Orbis Biosciences Inc

Otsuka Holdings Co Ltd
Pantherics Inc
Pfizer Inc
PHI Therapeutics Inc
Polyrizon Ltd
Portola Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
Pyramid Biosciences Inc
Qurient Co Ltd
Ralexar Therapeutics Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Ribomic Inc
SCM Lifescience Co Ltd
Seelos Therapeutics Inc
Servatus Ltd
Shaperon Inc
Shulov Innovative Science Ltd
Sienna Biopharmaceuticals Inc
Signum Biosciences Inc
Signum Dermalogix Inc
Sosei Heptares
Spherium Biomed SL
StemRIM Inc
sterna biologicals Gmbh & Co KG
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Temisis Therapeutics
The Geneva Biotech Center SA
Therabest Co Ltd
Tianjin Hemay Bio-Tech Co Ltd
Tolerys SA
Torrent Pharmaceuticals Ltd
Transdermal Therapeutic Technologies LLC
Union Therapeutics AS
Vasomune Inc
VivaCell Biotechnology Espana SL
Voronoi

vTv Therapeutics Inc
Welichem Biotech Inc
XBiotech Inc
Xencor Inc
Zhejiang I-Biological Technology Co Ltd

I would like to order

Product name: Atopic Dermatitis - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/A821E518065EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A821E518065EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970